<SEC-DOCUMENT>0001104659-22-103155.txt : 20220927
<SEC-HEADER>0001104659-22-103155.hdr.sgml : 20220927
<ACCEPTANCE-DATETIME>20220927081624
ACCESSION NUMBER:		0001104659-22-103155
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220927
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220927
DATE AS OF CHANGE:		20220927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		221267387

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2226615d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220927">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_syn_syntheticbiologics.com_20220927 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220927_20220927 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20220927.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-09-27to2022-09-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-27</xbrli:startDate>
        <xbrli:endDate>2022-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20220927__20220927_z6mQlWMQl93"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_900_edei--DocumentPeriodEndDate_c20220927__20220927_zWyxLToY8102"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 27, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220927__20220927_zFBj6zDqumda"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityRegistrantName">SYNTHETIC BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20220927__20220927_zcfgTAtN7iI6"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20220927__20220927_z0ZapT1T8NO1"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20220927__20220927_zKZkvBhdDIm2"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20220927__20220927_z7KJEFgGcKw9"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220927__20220927_zTNPiMAl9C1k"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20220927__20220927_zwhdlTiCaKT5"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20220927__20220927_zuCH1PXha3Ac"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20220927__20220927_zuG0NbYZrnl8"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90F_edei--CityAreaCode_c20220927__20220927_zBQKH9n1wWPh"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20220927__20220927_zMJ3Ck01KRXa"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20220927__20220927_z8pdd8maNjti"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_905_edei--SolicitingMaterial_c20220927__20220927_zJPWV33MZFU7"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20220927__20220927_zN4BIHk2sVDj"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20220927__20220927_ziwbZZ1BiQ34"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which<br />
 registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20220927__20220927_zForutBBKEBl"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20220927__20220927_zLWEcB4xa0U4"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" name="dei:TradingSymbol">SYN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20220927__20220927_zjIvOnUjfqwc"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric> </span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20220927__20220927_zbYQ6frHCKkd"><ix:nonNumeric contextRef="From2022-09-27to2022-09-27" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 7.01.</b>&#160;&#160;&#160;<b>Regulation
FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 27, 2022,
Synthetic Biologics, Inc. (the &#8220;Company&#8221;) issued a press release announcing positive outcome from the Data and Safety Monitoring
Committee (&#8220;DSMC&#8221;) review of results from the first Cohort of the Company&#8217;s Phase 1b/2a randomized, double-blinded,
placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention
of acute graft-versus-host-disease (aGVHD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in this
Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The press release furnished
as Exhibit 99.1 to this Current Report on Form 8-K includes &#8220;safe harbor&#8221; language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained therein are &#8220;forward-looking&#8221; rather than historical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 8.01.</b>&#160;&#160;&#160;<b>Other
Events.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 27, 2022,
the Company issued a press release announcing positive outcome from the DSMC review of results from the first Cohort of the Company&#8217;s
Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant
(HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key data and conclusions disclosed in the press release include:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cohort 1 enrolled 19 patients who received at
least 1 dose of study drug (SYN-004 or Placebo randomized 2:1). Sixteen patients received at least one dose of intravenous (IV) meropenem
and 12 of these patients completed sufficient doses of IV meropenem to be evaluable towards the study endpoints. The study is on-going
and remains blinded; however, key findings from blinded data for Cohort 1 are included below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adverse events (AEs) and serious adverse events
(SAEs) observed in Cohort 1 were typical of those observed in allo-HCT patients and no AEs or SAEs were determined to be related to study
drug treatment by the investigators.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">A total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations
including sepsis.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">One patient died 14 days after the last dose of study drug (within the 30-day reporting period) due to
sepsis that was not related to study drug.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Consistent with previous studies of SYN-004 in
healthy volunteers, SYN-004 was not observed in blood samples from the majority of the evaluable patients.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">o</td><td style="text-align: justify"><span style="color: windowtext">A total of 3 plasma samples (~2% of all analyzed samples) had low but
quantifiable levels of SYN-004 using a sensitive ECL assay.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">None of the 3 ECL positive plasma samples was found to contain active SYN-004 using a functional enzyme
activity assay.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Meropenem pharmacokinetics were as expected for
this patient population.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on a review of the safety and pharmacokinetic
data, the DSMC has recommended that the study may proceed to enroll Cohort 2 in which study drug (SYN-004 or Placebo) will be administered
in combination with the IV beta-lactam antibiotic piperacillin/tazobactam.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01. Financial
Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br />
Number</b></span></td>
    <td style="vertical-align: top; width: 2%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 88%; padding-right: 0.8pt"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><a href="tm2226615d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><a href="tm2226615d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated September 27, 2022</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: September 27, 2022</span></td>
    <td colspan="3"><span style="font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 42%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name:</span></td>
    <td><span style="font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer and Chief Financial Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4d6GSXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeyiSMJURJKhMo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB5GpJJA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2226615d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: left; margin: 0"><IMG SRC="tm2226615d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Positive Outcome
of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic
Cell Transplant Recipients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>- The DSMC has reviewed the safety and pharmacokinetic
data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, September 27, 2022 &ndash;</B></FONT> Synthetic Biologics, Inc. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a diversified
clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today
announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase
1b/2a randomized, double-blinded, placebo-controlled clinical trial</FONT> of <FONT STYLE="color: windowtext">SYN-004 (ribaxamase) in
allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cohort 1 enrolled 19 patients who received at
least 1 dose of study drug (SYN-004 or Placebo randomized 2:1). Sixteen patients received at least one dose of intravenous (IV) meropenem
and 12 of these patients completed sufficient doses of IV meropenem to be evaluable towards the study endpoints. The study is on-going
and remains blinded; however, key findings from blinded data for Cohort 1 are included below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Adverse events (AEs) and serious adverse events (SAEs) observed in Cohort 1 were typical of those observed
in allo-HCT patients and no AEs or SAEs were determined to be related to study drug treatment by the investigators.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations
including sepsis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">One patient died 14 days after the last dose of study drug (within the 30-day reporting period) due to
sepsis that was not related to study drug.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Consistent with previous studies of SYN-004 in healthy volunteers, SYN-004 was not observed in blood samples
from the majority of the evaluable patients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">A total of 3 plasma samples (~2% of all analyzed samples) had low but
quantifiable levels of SYN-004 using a sensitive ECL assay.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">None of the 3 ECL positive plasma samples were found to contain active SYN-004 using a functional enzyme
activity assay.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Meropenem pharmacokinetics were as expected for this patient population.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on a review of the safety and pharmacokinetic
data, the DSMC has recommended that the study may proceed to enroll Cohort 2 in which study drug (SYN-004 or Placebo) will be administered
in combination with the IV beta-lactam antibiotic piperacillin/tazobactam.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven A. Shallcross, Chief Executive Officer
of Synthetic Biologics, commented, &ldquo;These encouraging data support the clinical advancement of SYN-004 and build on the growing
data that underscore its therapeutic potential. We remain on track to initiate the second cohort in Q4 2022, which is designed to evaluate
the combination of SYN-004 with piperacillin/tazobactam. We are very grateful for the tremendous support from Dr. Dubberke and his team
at Washington University as we take critical steps with the goal of improving standard treatment for these highly susceptible patients
by overcoming existing limitations of broad-spectrum IV beta-lactam antibiotics.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2226615d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Phase 1b/2a Clinical Trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ongoing randomized, double-blinded, placebo-controlled
Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis. The trial is designed to evaluate
the safety, tolerability, and potential absorption of oral SYN-004 (150 mg q.i.d. for a maximum of 28 days) into the systemic circulation
of allogeneic HCT recipients who receive an IV antibiotic to treat fever. To mitigate risk, Cohort 1 of the study administered meropenem
as the study-assigned antibiotic. Meropenem is a carbapenem antibiotic that is not metabolized by SYN-004. Patients in Cohorts 2 and
3 will be administered piperacillin/tazobactam and cefepime respectively, each of which can be metabolized by SYN-004. The trial is also
designed to evaluate potential protective effects of SYN-004 on the gut microbiome as well as generate preliminary information on potential
therapeutic benefits and patient outcomes of SYN-004 in allogeneic HCT recipients. The trial is expected to enroll up to 36 participants
with three sequential cohorts, each evaluating a different study-assigned IV beta-lactam antibiotic. Safety and pharmacokinetic data
for each cohort will be reviewed by an independent Data and Safety Monitoring Committee that will make a recommendation on whether to
proceed to the next IV beta-lactam antibiotic. More information on the study is available <U>here</U> (NCT04692181).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About SYN-004 (ribaxamase)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade
certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of Clostridioides
difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV
beta-lactam antibiotics to treat infection following conditioning therapy. Antibiotic-mediated damage of the gut microbiome in allogeneic
HCT recipients may lead to adverse outcomes including CDI, VRE colonization and potentially fatal bacteremia and aGVHD. A previously
completed placebo-controlled <U>Phase 2b clinical trial</U> of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated
dysbiosis. Patients who received SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well
as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage
company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the
acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal
and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust
and sustained anti-tumor response by the patient&rsquo;s immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus
designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant
physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used
IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection
(CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information,
please visit Synthetic Biologics' website at&nbsp;<U>www.syntheticbiologics.com</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2226615d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such
as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot;
 &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and include statements </I>regarding the encouraging
data supporting the clinical advancement of SYN-004 and building on the growing data that underscore its therapeutic potential, remaining
on track to initiate the second cohort in Q4 2022, which is designed to evaluate the combination of SYN-004 with piperacillin/tazobactam,
SYN-004 improving standard treatment for the highly susceptible patients by overcoming existing limitations of broad-spectrum IV beta-lactam
antibiotics, the potential protective effects of SYN-004 on the gut microbiome and generating preliminary information on potential therapeutic
benefits and patient outcomes of SYN-004 in allogeneic HCT recipients and the trial enrolling up to 36 participants with three sequential
cohorts, each evaluating a different study-assigned IV beta-lactam antibiotic<I>. These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which
are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set
forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current
expectations include, among others, the ability of SYN-004 to improve standard treatment for the highly susceptible patients by overcoming
existing limitations of broad-spectrum IV beta-lactam antibiotics, the ability to enroll the anticipated number of patients in the Phase
1b/2a clinical trial</I>, <I>Synthetic Biologics' ability to reach clinical milestones when anticipated, Synthetic Biologics' ability
to successfully combine and operate the business of Synthetic Biologics and VCN, Synthetic Biologics' and VCN's product candidates demonstrating
safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and
achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval
for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic
Biologics' and VCN's ability to promote or commercialize their product candidates for the specific indications, acceptance of product
candidates in the marketplace and the successful development, marketing or sale of Synthetic Biologics' and VCN's products, developments
by competitors that render such products obsolete or non-competitive, Synthetic Biologics' and VCN's ability to maintain license agreements,
the continued maintenance and growth of Synthetic Biologics' and VCN's patent estate, the ability to continue to remain well financed,
and other factors described in Synthetic Biologics' Annual Report on Form 10-K for the year ended December 31, 2021 and its other filings
with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is
provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><IMG SRC="tm2226615d1_ex99-1img001.jpg" ALT="">&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Calabrese</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ccalabrese@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syn-20220927.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWauJ2bOdzZR+eYkxtmB5bUn6/ygg9YXc8ioljUemweMG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220927" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20220927">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220927_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220927_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>syn-20220927_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>syn-20220927_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20220927.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2226615d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226615d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V /P# 2(  A$! Q$!_\0
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M%:,/#EW#%L,$_CWPYIEG!+HOG196T\2:)$R:A)AM0\)>&LO++^('[)O[3?\
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MM,\+XTVX)\0YFMD?ZC!^#OBKF/#KXJR[P_XFQ^2JFZ_M\)@:57$2P:7,\?#
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M>RCEBGM_[5@\+:1K%QIS7UM>Z?\ VE#9O>V%Y9^?97']_'['W[-'A?\ 8_\
MV;/A'^SEX*F2\T7X9^$=,T9]4DM8K27Q'KHGFU+Q/X@N8H@I\[6=7NKN]=F
M?,^PR%54+_%E\"1+_P 1+NNO'\KO^VA^TANE.TYC?P[\10\8C8L=K"XFA+X
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M]YI5Q#?>$]8\%ZAIUY<V%U>VT]U)<:AX@_MO4=-\O1AJ/[ _M&>/_P#@V]^
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M_BU;'(SX,B\2.X\7*B[5A$@L7\5K:'[#'$MB/LQ_L8_LNWP!NE 50%&Z,C(
M5G8-&5E:11AQ.)48$_("23PDWP<^&=QXQ3XA3^"_#,OCR/3CI,?C&3P]H3^)
MDTTJ4-D-9;33?M;;25$$D[PJ.%08&/ZMX9^E7C_[)PF4^*_ >5>*U3*\?4SK
MAO-\P_L6.89-GM!6R^MF<LWP.(CG&64VY6Q%",<ZPD>6,LOS9*D\/_#7&'T)
M,#1S-8_P3X^XG\(\/F^#PN0\:97EV88G%8+.N&\1_P CK^R(^WC+)\YJ**Y,
M+*^28URE?,LF3GS_ ,WW[,__  2;^*7Q7M;+QM\:]9U'X8^$-2WZC;Z$NE0:
MC\3O$$-RJO)/-+>QS-H'VI75YI_$*ZW>W+%/MNA,Q0C^AGX/?!OP3\#/AOX?
M^&GP^T_5=.\)>%+6ZMK#2KG4)M5O)Y+^ZN[W4-0NKJY=II[R\N[RXGG;*QAI
M,111\Y]D72[9$,:M,JD$':X1BI&TC>BJX?& )U87(PI$V57$AT^U/F93/FKL
MDSM^9000"=N< @'&>M?DGBGXT\=>+6)PU#B6IAH9!E>,AF61Y!DZIY3DN68Z
M,)TU4^HT(TZF)JJG.:ECL15KU)2G+V>6T%;F_=_!SZ.OA[X(X'$/A7"XG,N*
M,UP7]F<0<<\1XBIF?$F:8'2;I>RG.6586BZJ3^H8>G&FXI>US.O:P%0R<':0
M<$D]>_\ GZ@5^5?[8O\ P1O_ &$?VU]<O/&GQ0^'>I>$?B??M:R7WQ5^%&M'
MP;XWU2XL/.%E>ZZ\EEK'AKQ/J=FEQ-#;:KXI\.:SJ4-K*UFET+7$(_5T1*%"
M\X&<9QW_  I&A#='=!Z+L _5#7YWD>=YWPOCIYIPYF^<Y'C:\.2N\HS.I@.:
M,DN93E1=/VB;2<HZP<DIJ"FN<_:<PRG+,WPZH9O@J.8Q5WRU8J*WNK.^G]+;
M0_E\B_X-9?V*I+SS&^.O[4,^C,FW[#_;OPK,VS&3"9C\*_[/$7;:=)R>NZOU
MZ_91_8(_8[_X)T^ O$LGP@\':7X8"Z1>ZO\ $#XK^.K^SUCQUJNB:/+#K6H7
MOB3QQJ4,!L/#>B2VW]L_V#I$&C>&-.OHVU&UTFVN2\[?H']CB "J66,# B58
M@@]\>66+>Y8]!7(^/?AOX/\ BAX'\7?#?Q[I,?B3P3X\\.:SX1\7Z!>N\=KK
MGASQ#IDND:UI5U):FWN([?4;*>:.X:UFMYMTC,DB9Q7V7$GBYXJ\=8=93QMX
MB\3Y_P .UL7".+R;'U,$Z$\OC[O*EEM#+E7G%7G2AB922GR\\;Q4X^3EW!_#
M.1SIULGR/#T*V$O]3E.K*;C?5^_4=5T[[-J[>K3[_D0O_!</_@FMK_P(\5?&
M=_CCH36FE:3J\-U\'M?M)-,^+GB2XDBO!H^DZ9\/K^&6ZU6Q\9$HMAK,<[>&
M%\^-+[5HX#>)%_.%_P &YW[)+?&G]L_Q+^U9>>$KO0/A/^SM:^*;_P &V5W:
MR7>D7/Q*\76NL>#O#NC0:E-'):ZC-X \*7_C&^U"&.7^W/#6LWW@K4+Q;K^T
M(VB_??5_^#:__@F/J/B<^(-/\.?&KPWIQNUNF\'Z-\7M4GT#C&^./4_$.F:]
MXYMG?&?[0M?&,&L0]+74H!Q7['? _P#9Y^#O[-WPX\._"/X(>!M(^'?PZ\*V
ML-IHGAC0D=;2 1*5:\NY[E[B^U35[K._4==U6ZO=;U.58Y=0U"YEBB=/U7$>
M(OACP)P)XB\.^$TO$3,,R\5<+#)L[EQ?C<!AL/D'#2J0G4RK+:F C".)KU5[
M2/UJ$:5O:3DY/EIQ?R%+AOB7B'B#AC,N+\)EN'PW"G-+"O!XZEC*F83:5GB:
M<*%-PCS0@^63DKJ_+K(]<:%".IR0$_O90$%E <,JJY&&VJ&;J,, 1^2GAK_@
MC3^RIX-_;9N?V]]-UWXPS?&NY^)'C3XHOIMWXE\'2>!?^$A\=6>KV>KVHTF#
MP#;ZZ-(MXM9NGTZW/B8WD4D=N;F_NT61)?UT\L9!RW';(Q^/%((@/XF_$@_S
M%?SYE.?Y_D-+-(9#FV+R:6>Y?+*<W6$J\L<9ELVW/"5U&#5:@W:7LI.,927O
M2LFG^C8O+,)CW1^MTHU?JDN;"\ROR.RUOO%Z6TU**LH'G!0',6X+GC(.,XST
M(R?QK\F-'_X(V_LHZ/\ MN3?M[6VO?&&3XSS_$;7OBL^F7'B3P@_@<>(?$-G
M>V5[9+I,?@"+7/[&CCO96M;<^)FO4=8VFU"=0R/^MWV./>'WR\)Y>W<NS;C:
M>"A.2.3SC/.*=]EC[,X^0IP5Z'O]WK^GM597Q!GN0K&?V!FF*RC^V,OGE.<+
M"U7#ZSEE12Y\%4<4U7HMNSIRY8R4KMJUGGB\JP.8^Q^NX*C4^I9NLPP5VI^S
MM:U9:)PJ;WAJW9:GEWQ1^$'P^^-?P[\:?"GXG^';'Q=\/OB'X;U+POXM\+:G
M$EQIM_INK"?[:ZD(+BWO6DF2YM+V"=+C2[ZTL[_2I+&\MUG/X#2?\&O7_!/Q
M?$9UM/'O[32Z/]OCO5\(KXY^'J:.8XGW?V=<7K_"5O$E[ISQEK>2.^UVYG:!
MW47*,=X_I,6 *05DD '&W*;?Q^3//UH-NC JS.V>Y()'T^7'Y@UW\'\>^(?
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)59SEM:22L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139626473772896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 27,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNTHETIC BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2226615d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20220927.xsd" xlink:type="simple"/>
    <context id="From2022-09-27to2022-09-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2022-09-27</startDate>
            <endDate>2022-09-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-09-27to2022-09-27">0000894158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-09-27to2022-09-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-09-27to2022-09-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-09-27to2022-09-27">2022-09-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-09-27to2022-09-27">SYNTHETIC BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-09-27to2022-09-27">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-09-27to2022-09-27">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-09-27to2022-09-27">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-09-27to2022-09-27">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-09-27to2022-09-27">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-09-27to2022-09-27">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-09-27to2022-09-27">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-09-27to2022-09-27">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-09-27to2022-09-27">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-09-27to2022-09-27">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-09-27to2022-09-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-09-27to2022-09-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-09-27to2022-09-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-09-27to2022-09-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-09-27to2022-09-27">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-09-27to2022-09-27">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-09-27to2022-09-27">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-09-27to2022-09-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M='@//GL?)=-[*CG_5U/\!%!+ P04    "  +0CM5EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  M".U6JQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  +0CM5)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ "T([5660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  +0CM5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  M".U4F8(\U[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  M".U697)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ "T([56%2F$)I!   *A$  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  M".U6?H!OP
ML0(  .(,   -              "  :P,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ "T([59>*NQS     $P(   L              ( !B \  %]R96QS
M+RYR96QS4$L! A0#%     @ "T([5:K$(A8S 0  (@(   \
M ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  M".U4D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  M".U5ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2226615d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2226615d1_8k.htm">tm2226615d1_8k.htm</File>
    <File>syn-20220927.xsd</File>
    <File>syn-20220927_lab.xml</File>
    <File>syn-20220927_pre.xml</File>
    <File>tm2226615d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2226615d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2226615d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20220927_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20220927_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20220927.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20220927",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2226615d1_8k.htm",
      "contextRef": "From2022-09-27to2022-09-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://syntheticbiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2226615d1_8k.htm",
      "contextRef": "From2022-09-27to2022-09-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-22-103155-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-103155-xbrl.zip
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M9X\G4#3:%,%7)L0'J19RQ(A1DJ5E.A";)0@6@48"<4ZR02Y:&+XHD3M2NEB
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M@G81PP-5\YFM Q]\#JRP M.G-N.!9XZ(!^&\UQV)H>$ W@',-$P#14-L2S0
M.,!C>Q2U=;D)V'$<+J4&)D8>V?$8(^?,9BXUM[<:-@P.9&)9R>0RDN#=H\V)
M8//;I3^X)QI"*!2=X?)\+^R8*V#'N90T)/<3S 1GXZ7F D<U=,F?7,,'X6/6
M&MAA\N8E^^6BH^M%BS:_^L9:3FXZG)N,VJ+X*^ZQ$TF2W"@>+W3:2S+L1'-9
MGL:'-,"\XD00)W90B647I)#;#U5^YNP0CPQWU$-2/;LEN;R2@8Z[R5M!ZTM9
M_ZCYG)KOAVK>XJ:A@63LWA5X17"-9K*.O[WY]#&?O[H[^W"X41V?I^>5%7Q"
M .B0I&!>N]4"3:NYF()/G8B/U;N@9&3//QK^^AI>##7\QF7H,;%Z593%X(+N
M7G>[BZ+L9N&T<?&0\S[6OFY4TQ?3]<H:#X2DM1@E3_IVM:"G<SN=W=7T7_;]
M8P&O;P&E9 MH>%[ W"?MP!AT[N[44^-]OO":=C!'W4]O#7F6+NQHJUE#V/?U
MK6%#N54LL).Y#G,A6W*2RM;0"VQOA<D/,&9]6<P"VGZ;2I E!\[YV(&SR;I
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MP$M;7F#ZW@1JUW ]GU1Y'Z\^AAX_1K6HR;GI(Y%J)YNC!)8CG5O@HO0]HO,
M@O!TQS1PJ0*F.&#VK,/3&&6XW#1AJAHTBF)87QRM 09(NM** N&B:W3HD%H
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M#6YT_I]]JZXW.]5O7O?L3G]H9R\^#T[WSYVW;RMOWDB6_#]02P,$%     @
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M$NBP4$!=.A$M8%],S0UTRW;%:S6'+949;HW6%>\1(8B 68L88A5.G.85?9W
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MJ?W$-RGI+\>R/Y2[M!S[ TJ*7"%K,8J=_QO^D],.)"NRE/F<0'+\LB.F,A/
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M"A.(08RBZ!NSH5[8FY(-N!)5CPE%YW;?.BK4041%495UUK<DE.]<\-^@)]/
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M,C8V,35D,5\X:RYH=&U02P$"% ,4    "  +0CM5I?Q-0,T3  "@4   %@
M            @ $$+@  =&TR,C(V-C$U9#%?97@Y.2TQ+FAT;5!+!08
..!0 % $8!   %0@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
